Search
"In the study we tested the stability of ceftolozane/tazobactam at two clinically relevant concentrations following reconstitution and dilution in 0.9% sodium chloride in two different elastomeric devices, specifically in accordance with the requirements of the UK NHS Yellow Cover Document" Gilchrist et al (2023).
Ceftolozane and tazobactam stability in elastomeric devices

Extract:

We write with an update around the degradation profile and toxicity data of ceftolozane/tazobactam in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT) that we published within your journal. In the study we tested the stability of ceftolozane/tazobactam at two clinically relevant concentrations following reconstitution and dilution in 0.9% sodium chloride in two different elastomeric devices, specifically in accordance with the requirements of the UK NHS Yellow Cover Document.

Reference:

Gilchrist M, Jamieson C, Drummond F, Hills T, Seaton RA, Santillo M. Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT). JAC Antimicrob Resist. 2023 Apr 17;5(2):dlad047. doi: 10.1093/jacamr/dlad047. PMID: 37077650; PMCID: PMC10108881.